European Commission approves abiraterone acetate for mCRPC


Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July.

As in the USA, abiraterone acetate is indicated for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have previously received treatment with a docetaxel-based chemotherapy regimen.

The availability of abiraterone acetate through national health services in nations like the UK and Germany may still take a while to negotiate. However, for those in most of Europe who have health insurance (or can just afford to pay for the drug themselves), it is now legal to prescribe abiraterone acetate as the first important new oral therapy for the treatment of advanced prostate cancer since the introduction of bicalutamide (Casodex) back in the mid-1990s.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 1,185 other followers

%d bloggers like this: